SERT 5-HT3 5-HT1A Compound for Rapid Onset Depression Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current selective serotonin reuptake inhibitors (SSRIs) have limitations such as a slow onset of action, significant adverse effects like sexual side effects and sleep problems, and a fraction of patients do not respond to treatment, necessitating a compound with combined SERT, 5-HT3, and 5-HT1A activity for faster serotonin level increase and improved therapeutic efficacy.
Innovation Solution
The use of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine, which exhibits SERT inhibition, 5-HT3 antagonism, and 5-HT1A agonism, offering a faster onset of action and reduced adverse effects, thereby enhancing treatment efficacy for CNS disorders and cognitive impairment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If SSRI is used for treatment, then therapeutic effect is achieved, but onset of action is slow (weeks)
Solution Approach 1:
The patent combines three distinct pharmacological activities into a single compound: SERT inhibition (selective serotonin reuptake inhibition), 5-HT3 receptor antagonism, and 5-HT1A receptor agonism. This multi-functional approach allows the compound to simultaneously increase serotonin levels through reuptake inhibition and rapidly activate 5-HT1A receptors, bypassing the delayed onset typically associated with SSRIs alone.
Solution Approach 2:
The compound performs preliminary action by directly activating 5-HT1A receptors while inhibiting serotonin reuptake. This dual mechanism creates an immediate therapeutic effect rather than waiting for gradual serotonin accumulation, effectively preparing the system for rapid response to serotonin modulation.
2Reliability
If SSRI is used for treatment, then depression and anxiety are treated, but sexual side effects and sleep problems occur
Solution Approach 1:
The compound exhibits selective pharmacological activity at different receptor sites: it acts as a serotonin reuptake inhibitor, a 5-HT3 antagonist, and a 5-HT1A agonist. This localized action at specific receptor types allows therapeutic benefits while minimizing off-target adverse effects associated with non-selective SSRIs, particularly sexual side effects and sleep disturbances.
Solution Approach 2:
The patent converts the potential harm of serotonin overactivation into a benefit by using 5-HT3 antagonism to counterbalance excessive serotonin effects. The 5-HT3 blocking activity mitigates adverse effects like nausea and sexual dysfunction while the 5-HT1A agonism provides anxiolytic and antidepressant effects, transforming what could be harmful serotonin excess into a balanced therapeutic profile.
3Adaptability or versatility
If SSRI is used for treatment, then some patients respond, but a significant fraction of patients do not respond
Solution Approach 1:
The compound performs multiple functions simultaneously: it inhibits serotonin reuptake, blocks 5-HT3 receptors, and activates 5-HT1A receptors. This multi-functionality addresses diverse pathological mechanisms underlying depression and anxiety, making the treatment effective for patients who may not respond to single-mechanism SSRIs, thereby improving overall response rates and treatment consistency.
Data Source
AI summary
New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.